Inhibitors of endoglin activity for the treatment of fibrosis
Endoglin has been identified to play a functional role as a regulator of TGFβ1 signaling, particular in TGFβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGFβ1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.
1. A method of treating a fibrotic disease in a human subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a composition comprising an antibody or antigen-binding fragment thereof that binds endoglin and inhibits endoglin activity, wherein the fibrotic disease is selected from the group consisting of lung fibrosis, kidney fibrosis, and liver fibrosis.
2. The method of claim 1 , wherein said composition is administered in combination with an antifibrotic agent.
3. The method of claim 2 , wherein said antifibrotic agent is selected from the group consisting of: pentoxyphiline, tocopherol, vitamin E, pioglitazone, INT 747, peginterferon 2b, infliximab, ribavirin, glycyrrhizin, candesartan, losartan, irbesartan, ambrisentan, FG-3019, warfarin, insulin, colchicines, peginterferon 2a, etanercept, pirfenidone, nintedanib, and IL-10.
4. The method of claim 1 , wherein said fibrotic disease is lung fibrosis and said subject has interstitial lung disease.
5. The method of claim 1 , wherein said fibrotic disease is kidney fibrosis and said subject has diabetic nephropathy.
6. The method of claim 1 , wherein said fibrotic disease is liver fibrosis and said subject has nonalcoholic steatohepatitis (NASH).
7. The method of claim 1 , wherein said lung fibrosis is idiopathic pulmonary fibrosis.